Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by wyndeweston Aug 13, 2017 4:06pm
297 Views
Post# 26576279

At the risk of

At the risk ofhaving the shorts give me a star or two, I would ask why there has not been a hostile takeover at this price if  PLI has such great biotech discoveries? I'm long and will continue to be long as I have quite a bit invested here, however Pierre & Co. are being paid good salaries. The only payment I will receive is through share price increase.  For the past year and a half we have been grinding down in share price but Pierre still has majority control of his Company.  That' a good thing but I think we have reached a breaking point and I am worried that Pierre will continue to manage things as in the past. The quarterly report on Monday evening will have to be spectacular with upside numbers or what, a partnership or something. News of really good clinical data so far has managed to excite the market for a day or two only.  I sure wish we would hear from the FDA....soon....
Bullboard Posts